Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Completed
University of Pennsylvania
Phase 3
2005-02-01
The purpose of this randomized clinical trial is to evaluate the efficacy and safety of the
alpha adrenergic blocker Alfuzosin (Uroxatral) in men with relatively new onset of chronic
prostatitis/chronic pelvic pain syndrome (CP/CPPS). Alfuzosin is a once daily (10 mg
capsule), FDA approved medication for an indication in benign prostatic hyperplasia (BPH).
The effectiveness of alfuzosin in improving lower urinary tract symptoms in patients with BPH
has been documented in a number of placebo-controlled studies. A number of small studies have
also suggested that alfuzosin ameliorates CP/CPPS symptoms through a similar alpha-blockade
mechanism. This study will enable further testing of this hypothesis
Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Completed
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3
2005-02-01
The purpose of this randomized clinical trial is to evaluate the efficacy and safety of the
alpha adrenergic blocker Alfuzosin (Uroxatral) in men with relatively new onset of chronic
prostatitis/chronic pelvic pain syndrome (CP/CPPS). Alfuzosin is a once daily (10 mg
capsule), FDA approved medication for an indication in benign prostatic hyperplasia (BPH).
The effectiveness of alfuzosin in improving lower urinary tract symptoms in patients with BPH
has been documented in a number of placebo-controlled studies. A number of small studies have
also suggested that alfuzosin ameliorates CP/CPPS symptoms through a similar alpha-blockade
mechanism. This study will enable further testing of this hypothesis
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
